Pay in 4 interest-free payments of $6.48 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
Studies have shown that after stopping randomized treatments, the average weight gain of trial participants was 11.6 pounds or 1.9 percentage points in the semaglutide and placebo groups, respectively for 52 weeks during an extension phase
Kyowa Hakko Bio Co
The medication also induces significant weight loss, with patients losing an average of 15% to 21% of their body weight in the SURMOUNT obesity trials, with somewhat lower weight loss observed in patients with type 2 diabetes
We established that this is likely a consequence of GLP-1RA treatment, rather than a general change associated with weight loss, because it was not evident with other agents (amylin) yielding similar weight loss and did not occur in the weight-matched group
US$ 23.39
US$ 21.95
US$ 28.45
US$ 22.83
